Whole cohort characteristics
| . | Whole cohort (N = 392) . |
|---|---|
| Age (y) | 72 (64-77) |
| Sex | |
| Female | 126 (32) |
| Male | 266 (68) |
| Type of MDS | |
| Primary | 289 (74) |
| Therapy-related | 103 (26) |
| Treatments | |
| HMA | 165 (42) |
| HMA/venetoclax | 30 (8) |
| Intensive chemotherapy | 10 (3) |
| Low-intensity treatment | 36 (9) |
| None/supportive | 147 (38) |
| Unknown | 4 (1) |
| SCT | 114 (29) |
| Transformed to AML | 103 (26) |
| Median follow-up (mo) | 26 (10-52) |
| . | Whole cohort (N = 392) . |
|---|---|
| Age (y) | 72 (64-77) |
| Sex | |
| Female | 126 (32) |
| Male | 266 (68) |
| Type of MDS | |
| Primary | 289 (74) |
| Therapy-related | 103 (26) |
| Treatments | |
| HMA | 165 (42) |
| HMA/venetoclax | 30 (8) |
| Intensive chemotherapy | 10 (3) |
| Low-intensity treatment | 36 (9) |
| None/supportive | 147 (38) |
| Unknown | 4 (1) |
| SCT | 114 (29) |
| Transformed to AML | 103 (26) |
| Median follow-up (mo) | 26 (10-52) |
Data shown as median (interquartile range) or number (%). Low-intensity treatment refers to lenalidomide, luspatercept, investigational, or small-molecule inhibitor.